Explore our content
Select a filter.
Digital transformation in life sciences
How pharma and medtech can shift from doing digital to being digital
Digital transformation is no longer a buzzword—it’s a strategic imperative. How can life sciences companies advance their capabilities and take a more holistic view of their digital strategies?
Breaking barriers to digitalization in biopharma
The pandemic's impact on R&D and commercial operating models
The COVID-19 pandemic has changed the way biopharma does business, from trials to manufacture to sales. Once things get back to normal, will it be business as usual or will the industry evolve and implement learnings from this period?
How life sciences and health care can improve their cyber posture
A new approach to cyber risk reporting
In October 2020, three US agencies joined forces to issue a stark warning to hospitals and healthcare providers: Ransomware attacks are on the rise—and institutions need to take immediate action to protect themselves.
Enhancing clinical trial diversity
Stakeholder perspectives on advancing research through representative clinical trials
Racial and ethnic diversity among clinical trial participants is important to support science-driven strategies aimed at understanding the needs of those who are affected by the disease or condition being investigated. How can the biopharma industry achieve this? The answer lies in multistakeholder partnerships.
Measuring the return from pharmaceutical innovation 2021
Our latest report looks at the current state of R&D returns for 15 leading biopharma companies from May 2019 to April 2020, the impact of the pandemic on R&D pipelines during 2020 and identifies lessons that can help change the R&D paradigm towards a future with higher returns.
Rethinking market access
Delivering on the promise of therapeutic innovation
Market access strategy is critical to therapy launch success, but traditional approaches can lack nuance. Our research suggests that an archetype-based approach to enable targeted market access strategies may be more useful.
Cell and gene therapy
Opportunities and challenges to personalized medicine
Advancements in next-generation cell and gene therapies are fulfilling the promise of personalized medicine and attempting to cure and heal patients rather than ameliorating symptoms. Multiple approved products have been launched in global markets and the number of clinical trials continues to grow.
Never the same again: How COVID-19 created seismic change in global life sciences regulations
A global report for life sciences executives and regulators
COVID-19 accelerated global scientific and regulatory innovation and collaboration in the life sciences industry. To stretch to new limits, the momentum must continue.
Regulatory changes in the future of health
Engaging with regulators and staying abreast of legislative and regulatory activity will be as important as ever
Responding to new or changing regulations is a persistent challenge for health care stakeholders, and it is one that is not fading away anytime soon.